A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and ...

系统性红斑狼疮（Systemic Lupus Erythematosus, SLE）是一种系统性自身免疫病，以全身多系统多脏器受累、反复的复发与缓解、体内存在大量自身抗体为主要临床特点，如不及时治疗，会造成受累脏器的不可逆损害，最终导致患者死亡。

Two studies have reported promising results on the use of rituximab for the treatment of graft rejection in pediatric and young adult renal transplant recipients. Billing et al.'s pilot study ...

此次SCTB35注射液再次获批临床，意味着神州细胞即将启动该双抗药物在自免疾病患者群体中的临床研究。期待随着前沿科学和药物机理研究的继续深入，可以助力更多更好的创新疗法诞生，为患者带来更优的治疗选择。

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...

商报全媒体讯（椰网/海拔新闻记者 孙鑫 通讯员 徐璐 ...

To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.

H.C. Wainwright在周五维持了对Adicet Bio Inc. (NASDAQ:ACET)股票的中性评级，此前该公司宣布了GLEAN第1期研究的积极生物标志物数据。该研究评估了Adicet Bio的现成gamma delta T细胞产品候选ADI-001（带有抗CD20 CAR）在复发或难治性非霍奇金淋巴瘤(NHL)患者中的表现。 Adicet Bio于9月19日报告，ADI-001导 ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...